About UDP-galactose translocator
UDP-galactose translocator (SLC35A2) is a protein
from Homo sapiens identified by UniProt accession
P78381, 396 residues long.
MolForge cross-references it against 0 known binders and
256 disease associations.
Target properties
| Protein name | UDP-galactose translocator |
| UniProt accession | P78381 |
| Gene | SLC35A2 |
| Organism | Homo sapiens |
| Length | 396 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (256)
Diseases linked to this target (Open Targets).
- SLC35A2-congenital disorder of glycosylation · score 0.83
- congenital disorder of glycosylation · score 0.53
- Intellectual disability · score 0.46
- genetic disorder · score 0.41
- epilepsy · score 0.37
- congenital disorder of glycosylation type II · score 0.37
- X-linked complex neurodevelopmental disorder · score 0.37
- Epileptic encephalopathy · score 0.26
- West syndrome · score 0.12
- developmental and epileptic encephalopathy, 1 · score 0.12
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P78381-F1 | alphafold | PREDICTED | 79.60 | — |
Amino-acid sequence (396 residues)
MAAVGAGGST AAPGPGAVSA GALEPGTASA AHRRLKYISL AVLVVQNASL ILSIRYARTL PGDRFFATTA VVMAEVLKGL TCLLLLFAQK RGNVKHLVLF LHEAVLVQYV DTLKLAVPSL IYTLQNNLQY VAISNLPAAT FQVTYQLKIL TTALFSVLML NRSLSRLQWA SLLLLFTGVA IVQAQQAGGG GPRPLDQNPG AGLAAVVASC LSSGFAGVYF EKILKGSSGS VWLRNLQLGL FGTALGLVGL WWAEGTAVAT RGFFFGYTPA VWGVVLNQAF GGLLVAVVVK YADNILKGFA TSLSIVLSTV ASIRLFGFHV DPLFALGAGL VIGAVYLYSL PRGAAKAIAS ASASASGPCV HQQPPGQPPP PQLSSHRGDL ITEPFLPKLL TKVKGS
Explore UDP-galactose translocator with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets